ONCAlert | Upfront Therapy for mRCC

Genomic Testing VIEW MORE >>

In an interview with Targeted Oncology, Carl Morrison, MD, DVM, senior vice president Roswell Park Comprehensive Cancer Center, discussed the rationale for evaluating the Ion Torrent-based approach to predicting response to immunotherapy. He highlighted the importance of this in the clinical setting and advances are necessary to further validate this as a biomarker of response.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.